Abstract. According to Global Health in 2013, it was estimated that there were 508 000 women deaths in the world in the year 2011 caused by breast cancer. Even though cancer can be treated with different treatments for example: immunotherapy, radiotherapy and chemotherapy surgical operation, this disease continues being a severe medical problem. For that reason it has to be found another methods for cancer treatment. The discovery of new drugs with better activity and less toxicity for the treatment of Breast Cancer is a goal of the major importance. In this sense, theoretical models as QSAR can be useful to discover new anti-breast cancer drugs. For this reason, we developed a new multi-parameter-QSAR (mp-QSAR) model to discover new drugs. However, almost all the computational models known focus in only one target or receptor. In this work, Breast cancer type 1 susceptibility protein, ATP-binding cassette sub-family G member 2, Human breast cancer cell lines, Peroxisome proliferator-activated receptor gamma/nuclear receptor coactivator 3, nuclear receptor coactivator 3 and STE20-related kinase adapter protein alpha were used as receptor inputs in the model. A linear technique like Linear Discriminant Analysis (LDA) is our statistical analysis, and we compared with others models to seek alternative multi-target models for inhibitors of some of these receptors. In so doing, we used as input Topological Indices, in specific Wiener, Barabasi and Harary indices calculated by Dragon software. These operators quantify the deviations of the structure of one drug from the expected values for all drugs assayed in different boundary conditions or parameters (type of receptor, type of assay, type of target, target mapping). The best model correctly classifies as active compounds 84.00 % and non-active compounds (99.06 %) in the training series. Overall training performance was 95.91%. Validation of the model was carried out by means of external predicting series. Overall predictability performance was 95.52%. By the first time, the present work reports the attempts to calculate within unified framework probabilities of new anti-Breast cancer drugs.
INTRODUCTION
According to Global Health in 2013, it was estimated that there were 508 000 women deaths in the world in the year 2011 caused by this cancer. It has been found that breast cancer disease has led to an internationally increase in mortality. Even though cancer can be treated with different treatments for example: immunotherapy, radiotherapy and chemotherapy surgical operation, this disease continues being a severe medical problem. For that reason it has to be found another methods for cancer treatment. Between these diverse use of treatment, chemotherapy is the one that has cause the most impact in cancer (1) .
As said before, the field in the research of better anti-cancer chemotherapies is getting bigger as time passes, as breast cancer is recognized as one of the main cancers that are causing feminine mortality. Chemoinfromatics is an area that has been widely used in these researches, making it as one of the most important fields. Basing on Chemoinformatics, there exists a multi-target model (mt) where by a big and heterogeneous database of several compounds is designed. In this model, the compounds are categorized as being active or inactive. Form these molecules, a portion of them were obtain in order to calculate there was a positive relationship and if it contributed to the blockage of breast cancer (2).
In this study, some proteins that were found to be related to breast cancer and used in this QSAR are Breast cancer type 1 susceptibility protein, Peroxisome proliferator-activated receptor gamma, STE20-related kinase adapter protein alpha, ATP-binding cassette sub-family G member 2, Human breast cancer cell lines, and Nuclear receptor coactivator 3 (3) .
Some enzymes related to breast cancer were found to be useful in the treatment of this disease. If the expression of breast cancer susceptibility gene 1(BRCA1) is lost, breast cancer starts to progress. It has also been found that this gene product initiates cancerous cell migration. Gene expression analyses demonstrate that several of these proteomic hits are differentially expressed between early and advanced stage EOC thus suggesting clinical relevance of these proteins to disease progression (3) .
The design of new enzyme inhibitors for the treatment of anticancer creates a main objective. From our point of view, QSAR techniques may be very helpful in this case. Unfortunately, some QSAR techniques predict new outcomes only for one specific assay. We can avoid this by developing a new Multi-target/Multiplexing QSAR models. These approaches are useful to process very large collections of compounds assayed against multiple molecular or cellular targets under different assay conditions (cj) as is the case of ChEMBL (4, 5) . This phase is significant for the Cheminformatics` future. QSAR models can foretell the results of the assay of different drugs for multiple targets. Nevertheless, QSAR models cannot foretell diverse results for a given sequence of targets when changed under a set of definite assay conditions for each target. Luckily, the new QSAR is not only useful for different targets but also to different multiplexing assay conditions (cj) for all targets.
A diverse topological indices (TIs) of molecular graphs (G) can be used to speed up the procedure of codification of the molecular arrangement of drugs in Cheminformatics studies. Topological Indices (TIs), also charge transfer indices and their different variants, can be consider as useful in the field of Cheminformatics. For example, in the study of the HIV-1 RT inhibitory activity of thiazolidinones with different TIs, have been found to be accurate in predicting the activity of these same compounds (6) . By the first time we used TI molecular descriptors developed by Wiener, Barabasi and Harary indices to develop one multi-target/multiplexing QSAR model for inhibitors of 6 different enzymes.
MATERIALS AND METHODS

Computational methods.
Techniques in Cheminformatics are capable to predict new drugs only for one specific illness, organism, assay, etc. In this work we evade this problem developing a new Multi-target QSAR model. These methods are powerful when we need to process very large collections of compounds or drugs assayed against multiple molecular or cellular targets in the different assay conditions or in different targets; as in the case of ChEMBL. A general data set composed of more than 17,000 drugs was downloaded from the public database ChEMBL (4, 5) . This dataset includes drug number (Nd) = 16750 drugs and/or organic compounds previously assayed in different multi target assay conditions (cj). Every drug evaluated in different rt receptors were assigned to 1 out of 2 possible activity classes: active (C = 1) or non-active compounds (C = 0). One compound may lead to 1 or more statistical cases because it may give different outcomes (statistical cases) for alternative biological assays carried out in diverse sets of multiple conditions. In this work, we defined cj according to the ontology rt => (au, cj, rt, te, sx). The different conditions that may change in the dataset are: different: receptors (rt), biological assays (au), molecular or cellular targets (te), or standard type of activity measure (sx). Notably, multi-target QSAR models are able to predict the results of the assay of different drugs for multiple targets. Fortunately, the new class of mt-QSAR models applies not only to different targets but also to different multi target assay conditions (cj) for all targets.. The different steps to develop our model are first, we calculate the molecular descriptors using Di of a given i th compound using one or more software for the generation of molecular descriptors. Next, we expand the raw dataset of molecular descriptors adding new variables with the form of Box-Jenkis Operators or moving averages ΔDij = Di -<Dij>. We can use both classes of descriptors to formulate linear and no-linear models. Where, Sij is a numerical score of the biological activity of the i th compound measured under the j th assay defined by the set of conditions cj. In these models, the average <Dij> = <Di(cj)>, used to calculate ΔDij values, is the average of the Di for different compounds and do not runs over a time domain but over a set of molecular descriptors that obey a given limit condition cj. (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Last, we upload the input values in order in the Statistic or Machine Learning software to run different algorithms and seek different linear and non-linear models. In this work, we are going to use STATISTICA (7).
In total we analyzed N > 17000 statistical cases, which each one have been assayed in at least one out of the assays, Number (Na) = 3 possible assays. For each one of these assays the dataset studied presents, for each drug, at least one out of Number Standart Types (Ns) = 17 standard types of biological activity measures in turn carried out in at least one out of Number Receptor Nr = 6 receptor. The values are reported in ChEMBL with three different levels of Curation Number (Nc) = 3 (expert, intermediate, or auto-curation level).
Theoretical model
In order to search the high-throughput mt-QSAR model we used the linear discrimant analysis (LDA) module of the software package STASTICA 6.0 (18) . The model developed presented the general form. Where, S(mj) = S(di, au, cj, rt, te, sx) is a real-valued variable that scores the propensity of the drug to be active in multi target assays of the drug depending on the conditions selected cj. The statistical parameters used to corroborate the model were: Number of cases (N), Canonical Regression coefficient (Rc), Chi-square statistic (χ 2 ), and error level (p-level); which have to be < 0.05 (19).
RESULTS AND DISCUSSION
Linear Multi-target model of drug-breast cancer receptor interaction.
The outcome of multi target breast cancer receptor inhibition depend both on drug structure and the set of assay conditions selected (cj) (20) . In this work, we report the first mt-QSAR model capable of predict whether a drug with a determined molecular structure may give or not a positive result in different multi target receptors rt. The best mt-QSAR model found was the following: 
The best model correctly classifies 667 out of 794 active compounds (84.00 %) and 2971 out of 2999 non-active compounds (99.06 %) in the training series. Overall training performance was 95.91%. Validation of the model was carried out by means of external predicting series, the validation correctly classifies 6083 out of 6148 nonactive compounds (>99%) and 1325 out of 1607 active compounds (82.45%). Overall predictability performance was 95.52%, see Table 1 . Where Sij = S(rt, au, sx, te) is a real-valued variable that scores the propensity of the drug to be active in multitarget pharmacological assays of the drug di carried out on the conditions The statistical parameters for the above equation in training are: Number of cases used to train the model (N), Canonical Regression Coefficient (Rc), Sensitivity (Sn), Specificity (Sp), and Accuracy (Ac) (7) . The probability cut-off for this LDA model is i p1(rj) > 0.5 => Ci(cj) = 1. It means that the i th drug (di) predicted by the model with probability > 0.5 are expected to inhibit the enzyme present in the j th assays carry out under the given set of receptors rj. This linear equation presented good results both in training and external validation series with overall Accuracy in training series above 90%. The values of accuracy higher than 75% are acceptable for LDA models; according to previous reports (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . The reader should be aware that N here is not number of compounds but number of statistical cases. One compound may lead to 1 or more statistical cases because it may give different outcomes for alternative biological assays carried out in different organisms with different enzymes as targets (31) . We used a big data from ChEMBL database, only using anti-breast cancer drugs and the model have good results. It is the first work on breast cancer in the mt-QSAR is used within the model using different enzymes, assays, and types of proteins.
CONCLUSION
It was possible to seek excellent predictors for DPIs using as input structural parameters of drugs and proteins. Theoretic multi-target QSAR models based on LDA and TI descriptors may become a useful tool in this sense. In this work, we developed a new LDA model using the Dragon descriptors, with a large data base using about 11000 different drugs obtained from the ChEMBL database. Is the first time that a mt-QSAR model is developed to study compounds with anticancer activity, study the main enzymes involved in breast cancer is paramount. In this sense, the model developed can help find more effective and less toxic drugs.
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